On December 14, 2013, Asieris Pharmaceuticals invited investigators and managers of clinical sites from Fudan University Shanghai Cancer Center, Shanghai Changzheng Hospital, Xin Hua Hospital (an affiliate of Shanghai Jiao Tong University, School of Medicine), The First Affiliated Hospital of Zhejiang University, The First Affiliated Hospital Of Soochow University, Sun Yat-Sen University Cancer Center and Tianjin Cancer Hospital, to participate in the investigators’ meeting, held in Shanghai, to introduce APL-1202’s phase II clinical protocol. The participants discussed actively about the protocol and related study designs, and many questions were raised and addressed. Overall, the meeting has accomplished its objectives.
